Cargando…

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens

In this viewpoint we would like to describe our results in terms of resistance pattern in Chilean patients with virological failure (VF) on raltegravir (RAL)-containing-regimens and highlight the need for the concomitant availability of genotypic resistance testing to integrase strand transfer inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrer, Pablo, Rodriguez, Consuelo, Sciaraffia, Alicia, Tordecilla, Rocío, Ramos, Veronica, Durán, Magdalena, Beltrán, Carlos, Afani, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646669/ https://www.ncbi.nlm.nih.gov/pubmed/33251020 http://dx.doi.org/10.1016/j.jve.2020.06.002

Ejemplares similares

HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients
por: Ferrer, Pablo, et al.
Publicado: (2013)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
por: Machado, Lucas de Almeida, et al.
Publicado: (2019)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
por: Ammar, Farah F., et al.
Publicado: (2012)

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
por: Fernández-Caballero, Jose Ángel, et al.
Publicado: (2016)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Treatment-shortening regimens for tuberculosis: updates and future priorities
por: Saluzzo, Francesca, et al.
Publicado: (2023)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
por: Reigadas, Sandrine, et al.
Publicado: (2010)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

What will it take to bring LAED medication regimens to young people?
por: Hosek, Sybil, et al.
Publicado: (2023)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA
por: Lam, Yu Ming Paul, et al.
Publicado: (2012)

Correction to 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2017)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
por: Noguera-Julian, Marc, et al.
Publicado: (2013)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
por: Hulgan, Todd, et al.
Publicado: (2014)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy
por: Carvalho, Sabrina, et al.
Publicado: (2022)

Containing the spread of COVID-19 in Ethiopia
por: Shigute, Zemzem, et al.
Publicado: (2020)

Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU?—a viewpoint
por: Kuindersma, Marnix, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sn0chb00u7gjssqcgf7bh2lqdf